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ABSTRACT 
An immunogenic murine fibrosarcoma cell line was genetically modified to express and produce the human 
R A N T E S chemokine stably. In in vitro chemotaxis assays purified recombinant h u m a n R A N T E S as well as 
h u m a n R A N T E S secreted by the modified murine tumor cells were strongly chemoattractant for mouse CDS"*" 
/Thy-1 + tumor-infiltrating lymphocytes (TIL). R A N T E S production did not alter the growth of these cytokine 
gene-modified tumor cells in vitro, but injection of RANTES-secreting cells resulted in the abolition of the 
ability of those cells to form solid tumors in vivo. The growth of tumors could be restored by co-administra-
tion of monoclonal antibodies that inhibit the function of various subsets of immune cells. For example, de-
pletion of CDS'*" T cells by antibody administration resulted in complete restoration of solid tumor formation 
by RANTES-secreting cells, whereas depletion of the CD4''' T cell population resulted in a partial restoration 
of tumor formation. Additionally, administration of an anti-CR3 monoclonal antibody known to inhibit the 
in vivo migration of macrophages also completely restored the tumorigenicity of RANTES-secreting fi-
brosarcoma cells. Thus, the h u m a n R A N T E S chemokine can abolish tumorigenicity of an immunogenic fi-
brosarcoma in an in vivo murine model, and this process is mediated by various subpopulations of immune 
effector cells. 
OVERVIEW SUMMARY members of the chemokine superfamily for their potential 
use, either alone or in combination, in gene therapy ap-
Members of the chemokine superfamily mediate potent and proaches that employ tumor cells as immunogens. 
selective chemoattraction of a variety of immune cell sub-
sets, which is concentration dependent. This important and 
novel biologic activity raises the possibility of using I N T R O D U C T I O N 
chemokines as adjuvants in cancer vaccine strategies. W e 
describe here the in vitro chemotactic capacity of R A N T E S T ^ h e chemokines are a TRiPARTirE superfame.y of immune 
for murine CDS"*" tumor-infiltrating lymphocytes (TIL). J. proteins witii promflammatory properties (Oppenheim ef a/.. 
Moreover, murine fibrosarcoma cells transfected vnth the 1991; Schall, 1991; Kelner et al, 1994). The stmctaral distinc-
cDNA encoding R A N T E S and secreting high levels of this tion that divides the superfamily into its three subgroups, C-X-
chemokine become nontumorigenic in immunocompetent C, C-C, and, most recentiy, C, has also been shown to delineate 
mice. The antitumor effect of R A N T E S is dependent on in- a general, although not absolute, distmction in the biological 
herent tumor immunogenicity and is mediated through the properties of diese molecules diat is dose dependent (Schall, 
participation of host-derived T cells and macrophages. 1991; Kelner et al, 1994). Whereas most C-X-C chemokines 
Thus, the general chemoattractant properties exhibited by tend to atttact and activate neuttophils but not monocytes, die C-
R A N T E S in vitro appear to be relevant in an in vivo model. C chemokines appear to atttact monocytes but not neuttophils 
These data warrant further investigation of other distinct (Schall, 1994). This distinction appears to be reflected by a speci-
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ficity at the level of the cloned receptors for these two classes of 
molecules, where C-C chemokine receptors have been shown not 
to bind C-X-C molecules and vice versa (Hohnes et al, 1991; 
Murphy and Tiffany, 1991; Gao et al, 1993; Neote et al, 1993; 
SchaU, 1994 and unpublished observation). 
The actions of the C-C chemokines are not limited to mono-
cytes, however. Various members of die C-C chemokine family 
have been shown to act differentially on basophds [monocyte 
chemotactic protein-1 (MCP-1) and R A N T E S ; Bischoff et al, 
1992; Kuna et al, 1992a,b] and eosinophils (RANTES and MIP-
la; Kameyoshi et al, 1992; Rot et al, 1992). Of particular in-
terest is the effect of the C-C chemokines on lymphocytes. 
R A N T E S was frrst shown to be a chemoatttactant for memory 
T cells in vitro (Schall etal, 1990), and tiiese fmdings have been 
extended to show that other C-C chemokines preferentially at-
tract drfferent lymphocyte subpopulations (Schall et al, 1993; 
Taub et al, 1993). The proadhesive properties for some of the 
C-C chemokines on lymphocytes have also been documented 
(Tanaka et al, 1993; Taub et al, 1993). Recendy, die C 
chemokine member, lymphotactin, has been cloned molecularly 
(Kelner etal, 1994; Kennedy etal, 1995). Lymphotactin clearly 
lacks the &st and thttd cysteines in the four-cysteine motif, but 
shares a great deal of amino acid similarity at its carboxyl ter-
minus with C-C chemokines. Lymphotactin is the only super-
famUy member to date to be selectively chemotactic to lympho-
cytes, as it does not atttact either monocytes or neuttophtis 
(Kelneretal, 1994; Kennedy ef a/., 1995). Thus, the chemokines 
could be involved in imparting leukocyte subset specificity in im-
mune cell ttafficking processes, and chemokines may be key links 
between lymphocytes, monocytes, basophils, and eosinophUs 
during inflammation and other immunoregulatory processes. 
Recentiy, the C-C chemokine monocyte chemotactic protein-
1 (MCP-1) and die C-X-C chemokuie IP-10 were shown to me-
diate antitumor effects in murine models (Rollins and Sunday, 
1991; Walter etal, 1991; Luster and Leder, 1993). W e designed 
experiments to test if the chemoatttactant properties of R A N T E S 
for monocytes and T lymphocytes observed in vitro were rele-
vant in an in vivo sitaation. In addition, we wished to investigate 
if tiie chemoatttactant effects of R A N T E S in vivo would have an 
impact on the growth of solid tumors in a murine model system. 
Therefore, murine tamor cells were engineered to produce the 
human R A N T E S chemokine stably, and the abtiity of the mod-
ified tumor cells to form solid tamors in recipient animals was 
measured and compared to die growth of tamors from unmodi-
fied cells. W e report here that RANTES-secreting immunogenic 
tamor cells fail to grow progressively in recipient animals and 
that this inhibition of growth is mediated through the actions of 
macrophages and T lymphocytes. Thus, die general chemoat-
ttactant properties exhibited by R A N T E S in vitro appear to be 
relevant in an in vivo model. Moreover, these properties suggest 
that die R A N T E S chemokine could play a role in the develop-
ment of tumor vaccine or other antitamor sttategies. 
MATERIALS AND METHODS 
Animals 
Female C57BL/6 mice (B6), 10 to 12 weeks old, were ob-
tained from the Animal Production Colonies, NCI Frederick 
Cancer Research and Development Facility, National Institates 
of Health (NIH), Frederick, M D . 
Tumors 
The weakly immunogenic MCA-205 sarcoma, syngeneic to 
B6 mice, was generated by i.m. injection of 0.1 ml of 0.1% 
methylcholanthrene ( M C A ) in sesame seed oil as described pre-
viously (Parker and Rosenberg, 1977) and was maintained in 
vivo by serial passage. The W P - 4 cell line that was used m these 
experiments is one of a series of clones derived from the M C A -
205 tumor. 
Briefly, a single cell suspension of fresh MCA-205 tumor 
from the second transplant generation was prepared as described 
elsewhere (Mul6 et al, 1985). Tumor clones were then grown 
in 96-well flat-bottomed tissue cultare plates (Costar, 
Cambridge, M A ) by limiting dtiution technique at 0.3 
cells/well. One such clone, designated WP-4, was mauitained 
as a monolayer cultare in complete medium (CM) containing 
RPMI-1640 (Biofluids, RockvUle, M D ) , 0.1 m M nonessential 
amino acids, 1.0 m M sodium pymvate (both from Biofluids), 
5 X 10"^ M 2-mercaptoedianol (2-ME, Aldrich Chemical Co., 
Milwaukee, WI), 0.3% fresh L-glutamine, 100 U/ml penicUlin, 
100 /Lig/ml stteptomycin (all from NIH media unit), 0.5 /ig/ml 
amphotericin B (Flow Laboratories, McLean, V A ) , and 1 0 % 
heat-inactivated FCS (Biofluids). 
Human RANTES gene transfer into WP4 tumor cells 
A human R A N T E S c D N A fragment composed of base patts 
1-411 (SchaU et al, 1990), containing the entire coding region 
including native signal peptide sequence of the R A N T E S pro-
tein, was subcloned into the mammalian expression vector 
pBJneo, which contains the selectable neomycin resistance 
gene. 
The immunogenic W P 4 tamor clone was transfected widi 
the pBJneo-RANTES constract. Transfections were performed 
using the Sttatagene CaP04 ttansfection kit (La Jolla, CA). 
Briefly, 5 X 10^ tamor cells were seeded on a 100-mm petri 
dish (Falcon, Lincoln Park, NJ). CeUs were cultured ovemight 
in D M E M supplemented witii 1 0 % heat-inactivated fetal calf 
semm (FCS; botii from Biofluids, Rockville, M D ) , 100 m M 
glutamine, 100 U/ml penicillin, and 100 pgjml stteptomycin 
(all from NIH media unit). One to twenty micrograms of 
pBJneo-RANTES was added to die tamor cells in tiie presetice 
of CaP04 and incubated at 37°C, 3 % CO2 for 18-24 hr. After 
the incubation, medium was removed from petri dishes and 
washed twice with D M E M . Fresh medium was added and plates 
were cultared for 24 hr at 37°C, 5 % CO2. Cells were split and 
allowed to incubate an additional 24 hr. Transfectants were se-
lected by die addition of 400 pg/ml of the neomycm analog 
G418 (GIBCO, Grand Island, N Y ) and maintained thereafter in 
G418. hidividual tamor clones were identified under die in-
verted microscope and removed from petri dishes using cloning 
cylinders (Bellco, Vineland, NJ). R A N T E S production by tiie 
clones was tested first by Westem blot analysis of culture su-
pematants. R A N T E S protein production was dien confttmed 
and quantitated by a RANTES-specific ELISA (Sadick et al, 
manuscript in preparation). Supematants were collected from 
5 X 10^ cells/ml cultured for 24 hr. 
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Generation of C D 8 ^ tumor-infiltrating lymphocytes 
Subcutaneous MC-38 tumor (syngeneic to B6 mice) was har-
vested in a sterile fashion and crashed with the hub of a syringe. 
The tumor was dien digested for 2 hr at room temperature in 
Hank's balanced salt solution (HBSS) (Biofluids, Rockville, 
M D ) containing 0.01% hyaluronidase type V, 0.002% deoxyri-
bonuclease type 1, and 0.1% coUagenase type FV (Sigma, St. 
Louis, M O ) as described previously (Mule et al, 1985). The 
mixture was passed dttough sterile 100-gauge nylon mesh 
(Nitex; Tedco, Inc., Elmsford, N Y ) to remove undigested frag-
ments, and the resulting single ceU suspension was then wasbed 
dttee times widi H B S S after osmotic lysis of red blood cells witii 
A C K lysuig buffer (B & B Research Laboratories Inc., 
Fiskeville, RI). To enrich for T ceUs, the suspension was then 
incubated for 45 min at 4°C with magnetic polystyrene beads 
(Dynal, Fort Lee, NJ) coated widi anti-Thy 1.2 antibody as de-
scribed previously (Yang et al, 1990). The bead-tamor-mfil-
ttating lymphocytes (TIL) conjugates were magnetically isolated 
and placed into cultare with recombinant interleukin-2 (IL-2) at 
30-150 IU/ml in complete medium (CM). Recombinant inter-
leukin-2 was kindly provided by the Chtton Corporation 
(EmeryvUle, C A ) (sp. act. = 18 X 10* lU/mg protein). Twenty-
four hours later (after spontaneous dissociation of TIL and mag-
netic beads), the TIL cultines were resuspended by shaking and 
the polystjTene beads were removed magnetically. The remain-
ing TIL were placed back into cultare with IL-2 at a concen-
ttation of 2.5 X 10^ cells/ml in 24-well cultare plates. 
Autologous tamor cells (stored at 4°C for up to 24 hr) ttradi-
ated with 100 Gy (for growth inhibition) were added back to the 
TIL culture at a concenttation of 2.5 X 10^ ceUs/ml as a source 
of antigenic stimulation. TIL cultures were subsequently res-
timulated every 10-14 days with freshly harvested and ttradi-
ated (30 Gy) tumor cell suspensions (which were lysed by TIL 
within 24 hr). By F A C S analysis, the TIL utUized in die exper-
iments were > 9 8 % Thy-1+, C D 8 + , C D 4 " and were cytotoxic 
in vitro, as reported previously (Yang et al, 1990). 
Tumor cell supernatants 
Supematants were collected from cultured W P 4 tumor lmes 
after 24 hr of hicubation at 37°C at a cell density of 1 or 2 X 
10* cells/ml. Tissue cultare was performed in C M usmg plas-
tic tissue culture flasks (Flacon Plastics, Oxnard, C A ) or 24-
well culture plates (Costar Corp., Cambridge, M A ) . 
Supematants were collected after centrifugation at 1,500 rpm X 
10 min. 
In vitro chemotaxis assays 
A 48-weU microchemotaxis chamber and thick nittocellu-
lose filter membrane with 5 /xm-diameter pores (Neuro Probe, 
Cabin John, M D ) was used to stady motUity of TD.. (Averbook 
et al, 1993). Dilutions of tamor supematants were placed into 
chambers above and below the filter membrane to generate con-
centtation gradients or equUibrium conditions. Wells above the 
membrane contained ceUs being tested for chemotaxis at a con-
centtation of 2 X 10* cells/ml m 45 pl. IL-2 was present in 
equal concenttations in the upper and lower weUs of the appa-
ratas to avoid effects from an IL-2 gradient. The apparatus was 
incubated for 2 hr at 37°C in 5 % C O 2 in humidified chambers. 
The membranes were removed, rinsed in a 10 m M buffered 
phosphate, 154 m M NaCl solution p H 7.2, fixed with 18.5% 
formalin, stained with Mayer's hematoxylin (SIGMA 
Diagnostics, St. Louis, M O ) , and cleared with propanol and xy-
lene. Membranes were placed on glass slides with type B im-
mersion oil (CargUle, Cedar Grove, NJ) and cover slips then 
applied. Analysis was performed with a Zeiss Axioskop mi-
croscope (model D-7082 Zeiss; Oberkochen, Germany) using 
a video camera (Ikegami Electtonics, Maywood, NJ) and an 
Optomax image analyzer (Model V from Optomax, Hollis, 
N H ) . Begttining at the top of the filter, the number of cells per 
200 X high-powered field was measured at successive 10-/nm 
intervals down through the nittoceUulose filter. Each weU 
("spot") on the filter was measured in three random areas and 
each sample was tested in triplicate wells. Video gain and 
Optomax counting parameters were determined once for each 
filter and remained unchanged for reading all wells on that fil-
ter. 
The foUowing terms are defined: 
1. EquUibrium conditions. Equal concenttations of a candidate 
factor above and below the filter membrane. 
2. Positive gradient. Concenttation of candidate factor in lower 
well greater than concenttation in upper well. 
3. Spontaneous migration. Cell migration with no factor above 
or below the filter membrane ( C M and IL-2 only). 
4. Chemokinetic effect. When migration under equilibrium 
conditions is greater than spontaneous migration but not sig-
nificantly different from migration in a positive gradient. 
5. Chemotactic effect. When migration in a positive gradient 
is significandy greater than both spontaneous migration and 
migration under equUibrium conditions. 
Statistical analysis was performed using the Kmskal-Wallis 
nonparametric analysis of variance on averaged triplicate val-
ues. A significant difference in overall migration between two 
conditions requtted that significant differences in cell counts be 
seen at three of four consecutive depths. 
In vivo tumor model 
RANTES-secreting and control tamors were harvested from 
flasks with trypsin/versene (Biofluids). Syngeneic B6 mice (be-
tween 5 and 10 per group) were injected s.c. with 1 X 10^ vi-
able cells of each tumor (in a volume of 0.1 ml HBSS). Tumor 
size, the product of the largest biperpendicular diameters, was 
measured with calipers at least twice weekly. All measurements 
were performed in a coded, blinded fashion, and were evalu-
ated for significance between groups by Stadent's f-test. N o an-
imals were excluded from the calculated mean and S E M of ta-
mor sizes shown in the figures and tables. 
In vivo depletion of T cell subsets by 
monoclonal antibodies 
Hybridomas producing rat IgG2b monoclonal antibody 
(mAb) agamst the C D 4 (GKl.5) and C D S (2.43) ceU-surface 
antigens were obtained from American Type Tissue Collection 
(Rockville, M D ) . The 2.43 m A b was harvested as ascites from 
sublethally irradiated (500 rad) DBA/2 mice. The GKl.5 m A b 
was purified from concenttated culture supematants using am-
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monium sulfate precipitation. For in vivo cell depletions, B6 
mice each received one i.v. injection of 1.0 ml diluted mAb, in 
which 0.2 nd of 2.43 monoclonal ascites fluid, or 300 fig of 
GK1.5 m A b was mixed witii HBSS, 24 hr before tamor mjec-
tion. Lymphocyte subset depletion (complete) was verified by 
flow cytometric analysis for CD4- and CDS-expressing cells of 
fresh splenocytes of mice receiving injections 2-4 days previ-
ously with mAb. Injection of dUuted ascites containing an IgG2a 
m A b (1A14, a gift from Dr. Richard B. Alexander, National 
Cancer Institate), dttected against the Thy-1.1 T cell antigen, 
served as an irrelevant conttol, as described previously (Karp 
ef al, 1993). Experimental groups contained between 5 and 10 
In vivo blockade of adhesion-promoting receptor on 
macrophages by SC6 m A b 
Purified 5C6 (Hutchings ef al, 1990) mAb was kindly pro-
vided by Drs. M. Stein and S. Gordon (Stt WUUam Dunn School 
of Pathology, Oxford University, Oxford, UK). 5C6 m A b was 
dUuted in HBSS to 400-500 /ig/ml and each mice received 1 
ml of dUuted 5C6 m A b i.v. beginning 24 hr before the s.c. in-
jection of tamor cells. Subsequent uijections of 5C6 m A b were 
given i.p. every other day for five total injections. 
R E S U L T S 
Stable RANTES chemokine production by genetically mod-
ified W P 4 tumor ceUs was obtained followmg cDNA ttansfer 
by ttansfection. Tumor ceU lines established from picked 
colonies growing in G418 selection media were screened for 
RANTES chemokine secretion by Westem blot analysis and 
ELISA. Four lmes (WP4-1, WP4-2, WP4-3, and WP4-12) were 
chosen for furtiier stady. The ttansfectants WP4-2 and WP4-3 
faded to secrete detectable quantities of RANTES, whereas 
WP4-1 and WP4-12 secreted >50 ng/ml and >130 ng/ml (per 
5 X 10^ cells per 24 hr), respectively. These levels of RANTES 
production were stable in vitro for at least 5 months (die extent 
of the duration of testing). Unmodified parental W P 4 tamor 
cells (WP4-no vector; WP4-NV) as weU as those ttansfected 
with the PBJ-neo constract only (WP4-NE0) were negative for 
RANTES production (not shown). 
The RANTES chemokuie detected in WP4-1 and WP4-12 
supematants by Westem blot and ELISA was dien evaluated 
for biologic function. Comparisons were made between super-
natants derived from cultares of die nonsecretuig conttol (WP4-
NV, WP4-NEO) tamor cells and die RANTES-secreting WP4-
1 and WP4-12 tamor cells, as weU as purified recombinant 
human RANTES. Murine TIL migration in response to these 
test substances in vitro was chosen as the parameter, as de-
scribed previously (Averbook ef al, 1993). TIL chemotaxis was 
tested utilizing a 48-well microchemotaxis chamber assay 
where tamor ceU supematants were tested at concentrations of 
50, 25, and 15% of die neat supematant, and purified bacteri-
aUy derived recombmant human RANTES was used at a fmal 
concenttation of 5 ng/ml. All experiments were done in a 
bluided fashion. The results from a representative experiment 
are shown in Fig. 1. Purified recombinant human RANTES pro-
tein elicited a sttong chemotactic response in all cases (Fig. 
lA-D), whereas equilibrium conditions showed no significant 
migration (not shown). Supematants from the WP4-NV tamor 
did not show any significant chemotactic activity (Fig. IA). 
Although the WP4-NEO tamor supematant showed a small de-
gree of chemotactic activity at high concenttations (Fig. IB), 
this effect was always much less than that seen in response to 
purified RANTES or die RANTES-contattung supematants. 
This WP4-NE0 chemoatttactant activity could be attributed 
possibly to the secretion of an endogenous chemotactic factor, 
as described previously (Averbook ef al, 1993). The difference 
in chemotactic activity between the WP4-NEO cells (i.e., min-
imal effect) versus nonttansfected parental W P 4 cells (i.e., no 
effect) might reflect the outgrowth of a selected Neo-resistant 
clone with endogenous chemotactic factor secretion that is also 
resident in the more heterogeneous parental tamor line but at a 
frequency below detection by the microchemotaxis assay. 
Culture supematants from both RANTES-secreting tamor lines 
(WP4-1 and WP4-12) demonsttated marked chemotaxis for the 
MC-38 TIL (Fig. IC and Fig. ID, respectively). Thus, human 
RANTES secreted from ttansfected W P 4 tamor cells had po-
tent chemotactic activity in vitro for murine Thy-1 """/CDS "''TIL. 
Although not apparent ui this particular example, m other ex-
periments the chemotactic activity of cultare supematants of 
RANTES gene-modified tamor cells was tittatable (data not 
shown). 
The in vitro growdi profiles of the WP4-1 and WP4-12 
RANTES-secreting tamor cell clones were compared to the 
nonsecreting ceU clones WP4-2 and WP4-3 and to WP4-NE0. 
The growth rates of the clones m cultare were unaffected by 
tiiett abUity to secrete human RANTES (not shown). After 10 
days, the number of cells in each culture was not significantly 
different. Thus, the presence of RANTES did not appear to have 
any dttect affect on die abiUty of W P 4 ceUs to proliferate in 
cultare. In addition, RANTES-secreting tumor ceUs did not 
have altered levels of M H C class I as detenmned by FACS (not 
shown). 
W e next tested the abUity of die RANTES-secreting W P 4 
tamor cells to form solid tamor masses in recipient animals af-
ter injection. Ten miUion cells from each of die two RANTES-
secreting cultures (WP4-1, WP4-12), tiie nonsecreting tamors 
(WP4-2, WP4-3), or die ttansfection conttol (WP4-NE0) were 
mjected subcutaneously in the back of recipient mice and die 
incidence of tamor fonnation in each group was followed over 
time. In every case, mice injected with die RANTES-secreting 
tamor ceUs faded to develop detectable solid tiunor masses out 
to day 51 whereas all otiier mice developed large tamor masses 
(Table 1). Moreover, tamor-free mice (n = 12) in die WP-1 and 
WP-12 RANTES-secretmg tamor groups all rejected a subse-
quent letiial challenge dose (1 X 10') of unmodified W P 4 
parental tumor cells given s.c. and remauied tamor-free for at 
least 100 days of observation. Thus, tamor immunity was 
elicited in vivo by die administtation of RANTES-secreting 
W P 4 tamor cells. 
To determine if immune effector cells were involved m die 
inhibition of solid tamor formation, we undertook to deplete or 
inhibit die function of various immune cells by the adnunistia-
tion of monoclonal antibodies to animals receiving RANTES-
secreting tamor cells. To deplete CD4+ and CD8+ T cell pop-














10 20 30 40 50 60 70 80 
1—I—;—I—I—^ 
10 20 30 40 50 70 80 
250 
10 20 30 40 50 60 70 80 
Filter penetration (\im) 
10 20 30 40 50 60 70 80 
Filter penetration (|i,m) 
RANTES 
5 ng/ml 
• 50 % D 25 % T 15% O Control 
FIG. 1. Chemoattractant activity of recombinant human RANTES and cell culture supematants from W P 4 ttansfectants for 
murine TIL. Results of in vitto chemotaxis assays employing thick filters where two parameters are measured: number of cells 
responding counted per high-power field (No./HPF; y axis) versus depth of penettation of the cells into the filter (x axis). The 
number of CD&^/Thy-1.2* murine TIL reponding to diluted cell culture supematants from parental W P 4 cells containing no vec-
tor (A), W P 4 cells stably ttansfected witii a N E O containing vector alone (B), and two ttansfectants that are stably producing 
RANTES, WP4-1 (C) and WP4-12 (D) are plotted and compared in each case to the number of ceUs responduig to purified 
RANTES or conttol medium. Dilutions are represented as percent of neat supematant. Migration of TIL in response to purified 
recombinant R A N T E S and to supematants from WP4-1 and WP4-12 ceUs was significant (p < 0.05) as assessed by 
Kmskal-Wallis nonparametric analysis of variance on averaged triplicate values. 
Table 1. Rantes-Secreting MCA-205 (WP4) Tumors 

















0/6^ (0 ± 0)<̂  
6/6 (9 ± 1) 
6/6 (7 ± 1) 
0/6 (0 ± 0) 
6/6 (8 ± 1) 
Day 51 
0/6 (0 ± 0) 
6/6 (16 ± 2) 
6/6(11 ± 1) 
0/6 (0 ± 0) 
6/6 (14 ± 1) 
Înjected S Q at 1 X 10'' ceUs/site. 
•"Number widi tamor/total. 
•^Mean tamor diameter (mm ± SEM). 
ulations, the mAbs GKl.5 and 2.43, respectively, were admin-
istered. In addition, we employed the 5C6 mAb, which has been 
shown to inhibit the migration of mouse macrophages in vivo 
effectively (Hutchings ef al, 1990). 
In the first set of experiments, the inhibition of macrophage 
migration by the administtation of the 5C6 antibody fuUy re-
stored the ability of RANTES-secretttig cells to form solid ta-
mors in recipient animals (Fig. 2A). In all animals that received 
both the WP4-12 ceUs and the 5C6 antibody, tamors developed 
very simUary to those in the conttols animals that had been in-
jected with WP4-NE0 cells. By conttast, no tamors formed m 
animals receiving WP4-12 ceUs in the absence of 5C6. 
SimUarly, the tamorigenicity of RANTES-secreting WP4-12 
cells could also be restored by the depletion of T cell subsets 
(Fig. 2B). Administtation of the anti-CD4 antibody rescued tu-
mor growth in recipient animals, though these tumors were 






























D WP4-12 + 
• WP4-T2 + 






























Tumor Diameter in m m 




10.9 ± 1.2 
3.0 ±1.5 
13.0 ±1.8 
FIG. 2. Identification of host immune cell populations mediating growth inhibition of RANTES-secreting tumor ceUs. 
Measurements of tamor size in recipient animals is plotted over time. A. Comparison of tumor growth in animals receiving WP4-
N E O cells, WP4-12 (RANTES-secretmg) cells, and a combmation of WP4-12 ceUs and the 5C6 antibody. B. Comparison of ta-
mor growth over time in animals receiving WP4-NEO and WP4-12 ceUs alone and WP4-12 ceUs in combination witii antibod-
ies depleting either CD4+ or CD8+ T ceUs, as weU as a conttol (anti-Thy 1.1) antibody. C. A summary of die results of a second 
sunUar experiment where tamor incidence and size in recipient animals were evaluated after 4 weeks. 
somewhat smaller than those in conttol animals. Anti-CDS an-
tibody tteatment also completely restored tamorigenicity, re-
sulting in tumors that were in this experiment larger than those 
in the conttols (Fig. 2B). A separate set of anunals yielded sim-
Uar results, as summarized in Fig. 2C. Again, administtation of 
either the anti-CDS or 5C6 antibodies fully restored the abUity 
of the RANTES-secreting cells to form solid tumors in recipi-
ent animals whereas the depletion of CD4'^ T cells resulted in 
a partial restoration of tamorigenicity (Fig. 2C). In this second 
set of animals, anti-CD4 tteatment resulted in tamors in four of 
six recipients and these tamors were significantiy smaller than 
in the conttol (WP4-NEO) animals, whereas 5C6 tteatment re-
sulted ui significantiy larger tumors. In no case did tamors form 
in animals receiving an irrelevant (anti-Thy-1.1) m A b tteatment 
(Fig. 2B and 2C). Thus, the ability of R A N T E S to inhibit tu-
mor growtii is mediated through the participation of immune 
cells. 
D I S C U S S I O N 
TTie C-C chemokine RANTES has been shown to be a po-
tent chemoatttactant for human monocytes and T cells in vitro 
(Schall ef al, 1990). W e undertook to examine tts properties in 
VIVO usmg a murine tumor model. This report shows diat un-
munogenic murine tamor cells that stably produce the human 
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RANTES chemokine lose their ability to form solid tumor 
masses in vivo. Furthermore, this loss of tumorigenicity appears 
to be mediated by various immune cells because the tumori-
genicity of RANTES-secreting cells in vivo is restored when 
CDS"^ and CD4+ T cells are depleted or when murine 
macrophage migration is inhibited. Thus, this study represents 
the fttst analysis of the functions of R A N T E S as produced from 
an in vivo source, and shows that the chemoatttactant proper-
ties of this chemokine for monocytes and T cells as predicted 
from in vitro assays using human cells appear to be broadly rel-
evant in this in vivo murine model. 
Although the predictions of the chemoatttactant potential of 
R A N T E S for leukocytes subsets obtained from both in vitro 
and in vivo experimental approaches generally conelate, some 
differences can been noted. For example, the original report de-
scribing human R A N T E S as a chemoatttactant for human 
monocytes and T cells suggested a preferential attraction of pre-
dominantiy CD4"^ ceUs of the memory phenotype (CD45RO*; 
Schall et al, 1990), whereas the data presented here suggest 
that human R A N T E S atttacts murine CDS"^ TIL in vitro and 
also affects murine C D S * function in vivo. These differences 
could be attributed to several factors. First, there may exist dif-
ferences in the fine specificity of the chemokine between hu-
m a n and murine species. Second, C D 8 * TEL may be preferen-
tially migrating in response to R A N T E S at the specific 
concenttations of chemokine used in these experiments. 
Concenttation-dependent specificity of atttaciton for T cell sub-
sets has been described for the related chemokine human MIP-
la (Schall ef al, 1993). Last, R A N T E S may be exhibitmg only 
an ability to preferentially atttact T cells of the memory or "ex-
perienced" phenotype. This is consistent with the results of both 
stadies, because the CDS"^ murine TIL are clearly "experienced" 
with respect to thett ability to recognize tamor cells and are 
therefore likely to be of the memory phenotype. Further ex-
periments are underway to examine this question more fully. 
The restoration of tamor growth by all tteatments witii anti-
bodies that inhibit T lymphocyte and macrophage function sug-
gests that R A N T E S can mediate the cooperation of these leuko-
cyte populations in antitumor defense. The details of this 
network are not yet clear but the experiments presented here 
may provide some clues. It is interesting that depletion of ei-
ther CDS"^ or C D 4 + T ceUs or the inhibition of the migration of 
macrophages all result in tumor growth, but subtle differences 
in the results obtained by the three different antibody tteatments 
may be important. For example, treatment with the anti-CD4 
antibody results in only a partial restoration of tumorigenicity 
by RANTES-secretmg tumors. Anti-CDS tteatment, however, 
or the inhibition of macrophage migration by the 5C6 antibody, 
restores the tamorigenicity of RANTES-secreting cells in all 
anunals, and the resulting tamor masses are as large or larger 
than those found in conttol mice receiving W P 4 - N E O cells, 
which do not secrete R A N T E S . Thus, it is possible that 
macrophages and C D S * T cells have primary roles in antitumor 
defense in this model, and the involvement of CD4"^ T ceUs is 
important but perhaps not essential. Because macrophages and 
distuict subsets of T cells may each have varying levels of im-
portance in mediating the rejection process, depending on 
whether the host immune system is "naive" or previously sen-
sitized to tumor, additional studies are needed to evaluate the 
effects of R A N T E S in models of vaccination and of treatment 
of established tumors. It should also be noted tiiat though 5C6 
has been characterized as an antibody that inhibits macrophage 
migration (Hutchings ef al, 1990), we cannot exclude a role 
for other CR3+ cells that 5C6 is lUcely to recognize. 
The importance of C D S * T cells in the abrogation of tumor 
growth in the presence of R A N T E S is supported by other ob-
servations. W e have performed a set of experiments where, 
rather than using immunogenic W P 4 cells, we have engineered 
a nonimmunogenic tumor cell line, 4JK (a clone of the M C A -
102 sarcoma; Karp ef al, 1993), to produce R A N T E S stably. 
Injection of such RANTES-producing, nonimmunogenic tamor 
cells (producing >50-200 ng/ml per 5 X 10^ cells over a 24-
hr period) into recipient animals does indeed result in the con-
sistent formation of solid tamors, but those tamors are more 
slowly growing (0.9 c m in mean diameter at day 19 after tu-
mor injection) than those in conttol animals (1.8 cm in mean 
diameter also at day 19). Thus, the immunogenicity of the par-
ent tumor cell may be important in the ability of the R A N T E S 
chemokine to eradicate tamor growth in vivo. 
One possibility is that in this system the immunogenic ta-
mor engenders a sttong endogenous T cell response, resulting 
in antitamor memory T cells, which are then recraited effec-
tively to the nascent tamor by R A N T E S . Nonimmunogenic ta-
mors would not trigger the same level of T cell reaction, but 
thett growth might stUl be inhibited by virtae of the capacity 
of R A N T E S to atttact a clone(s) of reactive T cells at low fre-
quency in the periphery as well as monocytes/macrophages. 
In preliminary immunization/challenge experiments, we 
have not observed any discemible increase in the capacity of 
inadiated RANTES-secreting W P 4 (or 4JK) tamor cells to im-
munize naive mice compared to its counterpart irradiated con-
ttol parental line. Therefore, the secretion of large amounts of 
this chemokine per se does not appear to increase the inherent 
immunogenicity of this particular tumor; similar results have 
been obtained with the nonimmunogenic 4JK tamor line as well. 
Thus, the in vivo antitumor effect of R A N T E S is more likely 
to be a dttect result of its chemotactic function on host immune 
cells. Further experimentation is necessary to elucidate the de-
tails of the mechanisms du-ough which R A N T E S mediates its 
immune cell dependent antitamor effects. In this regard, 
R A N T E S has recently been shown to mediate dttect activation 
of T cells (Bacon ef al, 1995). 
Anotiier C-C chemokine that has been reported to have an 
effect on the growth of tamors is MCP-1. Alfliough it has been 
shown that MCP-1-modified Chinese hamster ovary (CHO) 
cells wiU not form tumors in raimunodeficient nude mice 
(Rollins and Sunday, 1991) and tiiat MCP-1 ttansduction of a 
murine sarcoma conelates with a slower growth rate and an in-
creased macrophage content of die resulting neoplasms in 
BALB/c mice (Walter ef al, 1991), neither of tiiose stadies has 
reported the ablation of tamor growth in immunocompetent 
mice. In addition, neither dissects the immune mechanism of 
tamor inhibition, although bofli reports document an increase 
macrophage involvement in MCP-1-ttansduced tumors. 
Although dttect comparisons ofthe MCP-1 reports and die cur-
rent stady regarding R A N T E S are obviously flawed, it is in-
teresting to speculate that R A N T E S may be exhibiting a more 
potent antitamor effect by vtttae of its abUity to affect T lym-
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phocyte as well as macrophage recmitment and/or function. By 
conttast, die action of MCP-1 has been largely thought to be 
restricted to macrophages. A recent report by Luster and Leder 
(1993) demonsttated tiiat die C-X-C chemokuie IP-10 can in-
hibit tamor growth in vivo. In tiiat stady, the effect of IP-10 
was shown to be thymus dependent, but, unlike the present 
stady, the mechanism of tamor inhibition was not delineated, 
and in vivo depletion of immune ceU populations had not been 
performed. Dttect comparisons between chemokines using the 
same ceU lines and the same sttains of immunocompetent mice 
would undoubtedly be of use in determining the relative anti-
tamor efficacies of the various members of the superfamily. 
In summary, we have shown that murine tamor cells that 
have been engineered to produce the R A N T E S chemokine sta-
bly have a loss of tamorigenic capacity in vivo. This lack of ta-
morigenicity seems conelated with the function of T cells and 
macrophages in the host animal and level of inherent immuno-
genicity of the tamor. Thus, the chemoatttactant activities as-
cribed to the R A N T E S molecule from in vitro stadies may be 
relevant to in vivo immune ttafficking processes, and fliese 
properties might be exploited in certain antitamor sttategies that 
employ vaccines. 
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